


wherein,  $R_{01}$  and  $R_{02}$  are each independently a hydrogen atom, a trimethylsilyl group, a triethylsilyl group, a t-butyldimethylsilyl group, an acetyl group, a methoxymethyl group or a tetrahydro-4H-pyran-2-yl group;

Z is represented by formula (1-5),



in the above formula (1-5),

$R_{51}$  expresses  $-\text{CONR}_{511}\text{R}_{512}$ ,  $-\text{COR}_{513}$  or  $-\text{C}(\text{OH})\text{R}_{514}\text{R}_{515}$ , wherein  $R_{511}$  and  $R_{512}$  are identical to or different from each other, and they are a hydrogen atom or a  $\text{C}_1$ - $\text{C}_4$  alkyl group, or both the members together express a nitrogen-containing  $\text{C}_3$ - $\text{C}_8$  alkyl ring or a morpholino group in cooperation with the nitrogen atom to which they are bonded; and  $R_{513}$ ,  $R_{514}$  and  $R_{515}$  are identical to or different from each other, and they express a  $\text{C}_1$ - $\text{C}_4$  alkyl group;

*B*

R<sub>52</sub> expresses a methyl group, an ethyl group, a trifluoromethyl group or a pentafluoroethyl group.

<sup>2</sup>46. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>01</sub> and R<sub>02</sub> are both hydrogen atoms.

<sup>3</sup>47. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub> or -COR<sub>513</sub>.

<sup>4</sup>48. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub>.

<sup>5</sup>49. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>51</sub> is -COR<sub>513</sub>.

<sup>6</sup>50. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>51</sub> is -CONR<sub>511</sub>R<sub>512</sub>, and R<sub>511</sub> and R<sub>512</sub> are identical to or different from each other, and they are a methyl group or an ethyl group, or both the members together express an aziridine, pyrrolidine, piperidine or morpholino ring in cooperation with the nitrogen atom to which they are bonded.

<sup>7</sup>51. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>51</sub> is COR<sub>513</sub>, and R<sub>513</sub> is a methyl group or an ethyl group.

<sup>8</sup>52. (Amended) A vitamin D<sub>3</sub> compound or a pharmaceutically permissible solvate thereof described in Claim 45<sup>1</sup>, wherein, in the above formula (1), R<sub>52</sub> is a methyl group.

Amendment Under 37 C.F.R. § 1.111  
U.S. Application No. 10/035,211

*B1*  
*only*  
9 ~~53~~. (Amended) A pharmaceutical composition comprising a vitamin D<sub>3</sub> compound or pharmaceutically permissible solvate thereof described in Claim ~~45~~<sup>1</sup>, and a pharmaceutically permissible carrier.

---

**Please add the following new claims:**

---

*B2*  
10 ~~54~~. (New) A method for treating an inflammatory respiratory disease comprising administering to a subject a therapeutically effective amount of a vitamin D<sub>3</sub> compound according to claim ~~45~~<sup>1</sup>.

11 ~~55~~. (New) A method for treating an inflammatory respiratory disease according to claim ~~54~~<sup>16</sup>, wherein the inflammatory respiratory disease is at least one inflammatory respiratory disease selected from the group consisting of acute upper airway infection, chronic sinusitis, allergic rhinitis, chronic lower airway infection, pulmonary emphysema, pneumonia, bronchial asthma, tuberculosis sequela, acute respiratory distress syndrome, cystic fibrosis and pulmonary fibrosis.

12 ~~56~~. (New) A method of treating an inflammatory respiratory disease according to claim ~~55~~<sup>11</sup>, wherein the inflammatory respiratory disease is at least one acute upper airway infection selected from of the group consisting of common cold, acute pharyngitis, acute rhinitis, acute sinusitis, acute tonsillitis, acute epiglottitis and acute bronchitis.

13 ~~57~~. (New) A method of treating an inflammatory respiratory disease according to claim ~~56~~<sup>12</sup>, wherein the inflammatory respiratory disease is at least one chronic lower airway infection selected from of the group consisting of chronic bronchitis, diffuse panbronchiolitis and bronchiectasis.

Amendment Under 37 C.F.R. § 1.111  
U.S. Application No. 10/035,211

*B2*  
*contd*  
~~14~~ 58. (New) A method of treating a disease selected from the group consisting of malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, and dermatitis, comprising administering to a subject a therapeutically effective amount of a vitamin D<sub>3</sub> compound according to claim ~~45~~ 1

~~15~~ 59. (New) A method of treating hypercalcemia attributable to vitamin D excess, comprising administering to a subject a therapeutically effective amount of a vitamin D<sub>3</sub> compound according to claim ~~45~~ 1

~~16~~ 60. (New) A method of treating hypoparathyroidism, comprising administering to a subject a therapeutically effective amount of a vitamin D<sub>3</sub> compound according to claim ~~45~~ 1

~~17~~ 61. (New) A method of treating a metabolic disorder of cartilage, comprising administering to a subject a therapeutically effective amount of a vitamin D<sub>3</sub> compound according to claim ~~45~~ 1

---